The United States Supreme Court has temporarily lifted a lower-court ruling that would have ended mail-order access to mifepristone, the drug used in the majority of American medication abortions, granting what NPR describes as a one-week reprieve while the underlying appeals proceed. The lower-court decision, reported last week by the BBC, would have curtailed the telehealth-and-mail framework that the Biden-era Food and Drug Administration formalised in 2023 and that has since become the most common method of abortion in the United States. The administration of President Trump has not yet taken a formal position on the underlying merits; the Department of Justice’s brief at the certiorari stage was, by historical standards, unusually narrow. The reprieve is procedural, not substantive: the Court has not ruled on the merits, and the underlying litigation is expected to return to the docket within months.
The received wisdom
The dominant progressive framing treats the reprieve as a small, fragile mercy in an otherwise bleak post-Dobbs landscape — evidence that the conservative majority is not yet willing to ratify the most extreme positions of the Fifth Circuit, but that the underlying drug-access regime is one bad ruling away from collapse. On this account, the Trump administration’s tepid posture in the litigation is itself a strategy: outsource the policy outcome to friendly lower courts, decline to defend the FDA’s regulatory autonomy, and allow the judiciary to do politically what the administration has chosen not to attempt legislatively. The implied conclusion is that pro-choice institutions need to plan for a world in which medication abortion is regulated state-by-state, with the federal floor having been substantially eroded.
A different read
The progressive account captures something real about the legal trajectory, but it misses what is actually unusual about the Supreme Court’s handling of the case, which is the visible institutional caution. The Roberts Court’s posture on abortion since Dobbs has been, on close reading, more equivocal than either side will admit. The 2024 mifepristone case, FDA v. Alliance for Hippocratic Medicine, was decided 9-0 against the plaintiffs on standing grounds, in an opinion authored by Justice Kavanaugh that pointedly declined to reach the merits. The Court has, in the intervening eighteen months, granted certiorari sparingly on abortion-adjacent matters, and when it has spoken, it has done so on procedural grounds. The current one-week stay is consistent with that pattern: a judiciary that is, for the moment, reluctant to be the body that ends mail-order mifepristone access through anything but the most procedurally pristine vehicle.
This is, paradoxically, the kind of judicial behaviour that traditional conservatives — by which I mean conservatives in the Burkean sense, and not the legal-realist sense that has dominated the American right for forty years — should welcome and the legal-realist right should find frustrating. The case for Dobbs was, fundamentally, a case for legislatures over judges on contested moral questions. A Court that returns the abortion question to the political process and then declines to use procedural vehicles to resolve the next round of policy disputes from the bench is being faithful to the Dobbs logic. The legal-realist right, which had hoped Dobbs would inaugurate a long string of pro-life rulings on adjacent regulatory questions, has been visibly disappointed by this restraint and has spent eighteen months openly criticising the Chief Justice for the posture.
There is a deeper point about institutional design. The American constitutional system depends, in ways that have only become fully visible in the last twenty years, on the willingness of each branch to do its own work. When Congress declines to legislate on abortion access — as it has, repeatedly, declined since the Roe decision in 1973 — the gap is filled by either the executive (through agency rule-making) or the courts (through litigation). Both substitutes are, in the long run, inferior to legislation, because both are subject to reversal at every change of administration or every shift on the bench. The medication-abortion question would be substantially less fraught today if a previous Congress, on either side of the Roe divide, had legislated a federal framework that the FDA was implementing rather than improvising. The same is true of immigration, of war powers, and of the tariff structure that the Trump administration is now reshaping by executive order. The cost of legislative abdication is paid in judicial overload and in the politicisation of every administrative decision that touches a contested question.
The Trump administration’s narrow brief is, in this context, a small piece of the same pattern. A more institutionally ambitious White House would have either defended the FDA’s regulatory autonomy or asked Congress for a statute. Doing neither leaves the question to the courts and to the next election.
What to watch
Three signals will tell us where this lands. First, whether the administration files a more robust brief at the merits stage — silence here means the policy outcome is being outsourced. Second, whether a bipartisan working group in the Senate, however small, surfaces draft legislation: even an unsuccessful bill changes the political topography. Third, whether the Court takes the underlying case on the merits or disposes of it again on standing or ripeness grounds; the former would be uncharacteristic of the Roberts Court’s recent posture, the latter would confirm it.
— J